[go: up one dir, main page]

HUE054068T2 - Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények - Google Patents

Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények

Info

Publication number
HUE054068T2
HUE054068T2 HUE16783855A HUE16783855A HUE054068T2 HU E054068 T2 HUE054068 T2 HU E054068T2 HU E16783855 A HUE16783855 A HU E16783855A HU E16783855 A HUE16783855 A HU E16783855A HU E054068 T2 HUE054068 T2 HU E054068T2
Authority
HU
Hungary
Prior art keywords
lonafarnib
ritonavir
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HUE16783855A
Other languages
English (en)
Inventor
Patrick Gosselin
Aimesther Betancourt
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of HUE054068T2 publication Critical patent/HUE054068T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE16783855A 2015-04-21 2016-04-21 Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények HUE054068T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150721P 2015-04-21 2015-04-21
US201562153815P 2015-04-28 2015-04-28

Publications (1)

Publication Number Publication Date
HUE054068T2 true HUE054068T2 (hu) 2021-08-30

Family

ID=57144273

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16783855A HUE054068T2 (hu) 2015-04-21 2016-04-21 Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények

Country Status (9)

Country Link
US (3) US10835496B2 (hu)
EP (1) EP3285768B1 (hu)
JP (1) JP2018517673A (hu)
KR (2) KR20220147695A (hu)
CN (1) CN107530338B (hu)
DK (1) DK3285768T3 (hu)
ES (1) ES2844848T3 (hu)
HU (1) HUE054068T2 (hu)
WO (1) WO2016172342A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
EP3370723B1 (en) * 2015-11-04 2020-12-16 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR20180110127A (ko) 2016-02-19 2018-10-08 아이거 바이오파마슈티컬스 인코포레이티드 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US20030181355A1 (en) 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
BR9610745A (pt) 1995-12-08 1999-07-13 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il) metil-2-quinolinona inibindo a transferase da proteina farnesil
ES2248826T3 (es) * 1995-12-22 2006-03-16 Schering Corporation Amidas triciclicas utiles para la inhibicion de la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
AU6605196A (en) 1996-02-29 1997-09-16 Duke University Method of treating hepatitis delta virus infection
DK0988038T3 (da) 1997-06-02 2002-12-02 Janssen Pharmaceutica Nv Anvendelse af (imidazol-5-yl)methyl-2-quinolinon derivater til hæmning af glat muskelcelleproliferation
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
ID29241A (id) 1998-12-23 2001-08-16 Janssen Pharmaceutica Nv Turunan-turunan kinolin teranelasi-1,2
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU2001231763A1 (en) 2000-02-24 2001-09-03 Janssen Pharmaceutica N.V. Dosing regimen
BR0109716A (pt) 2000-03-29 2003-06-17 Univ Georgetown Uso de um nucleosìdeo ou um análogo de nucleosìdeo no tratamento de infecção viral por hepatite delta
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
ATE404670T1 (de) 2000-06-30 2008-08-15 Zymogenetics Inc Allelische variante des interferon-ähnlichen proteins zcyto21
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE60230017D1 (de) 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
ES2878403T3 (es) 2002-02-01 2021-11-18 Bend Res Inc Método para preparar dispersiones de fármacos amorfas sólidas homogéneas secadas mediante pulverización utilizando aparatos de secado por pulverización modificados
JP2006509041A (ja) 2002-10-23 2006-03-16 ザイモジェネティクス,インコーポレイティド Il−28およびil−29を用いるウイルス感染を治療するための方法
DK1668031T3 (da) 2003-08-07 2008-06-30 Zymogenetics Inc Homogene præparater af IL-29
CN1878540B (zh) * 2003-12-15 2012-02-29 科学与工业研究委员会 含pH敏感性聚合物的掩味的药物组合物
EP1750749A2 (en) 2004-04-02 2007-02-14 ZymoGenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
WO2005117864A1 (en) 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
US7148459B2 (en) 2004-07-01 2006-12-12 Harris Corporation Photon energized cavity and system
US20060111398A1 (en) 2004-11-05 2006-05-25 Fourie Anne M Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20070053933A1 (en) 2005-07-20 2007-03-08 Sheppard Paul O IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME
WO2007013944A2 (en) 2005-07-20 2007-02-01 Zymogenetics, Inc. Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
WO2007041713A1 (en) 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
WO2007064691A1 (en) 2005-12-02 2007-06-07 Nabil Habib Lab Treatment of cancer and other diseases
EP1998759A2 (en) 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US8372836B2 (en) 2006-10-17 2013-02-12 Bend Research, Inc. Spray dried formulation
WO2008137692A1 (en) 2007-05-03 2008-11-13 Link Medicine Corporation Treatment of synucleinopathies
US20090087483A1 (en) 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
WO2010009432A1 (en) 2008-07-17 2010-01-21 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
SI2421527T1 (sl) 2009-04-25 2018-09-28 F. Hoffmann-La Roche Ag Metode za izboljšanje farmakokinetike
WO2011088126A2 (en) * 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
ES2533213T3 (es) 2011-04-01 2015-04-08 Novartis Ag Tratamiento para infección con el virus de hepatitis B solo o en combinación con el virus de hepatitis Delta y enfermedades hepáticas asociadas
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
WO2013024494A2 (en) * 2011-08-18 2013-02-21 Hetero Research Foundation Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
GB201115635D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
HK1202801A1 (en) 2012-02-03 2015-10-09 吉联亚科学公司 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
AU2013337663A1 (en) 2012-11-02 2015-06-11 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
US9771344B2 (en) 2013-11-28 2017-09-26 Universiteit Gent Peloruside analogs
US11311519B2 (en) * 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3137078B1 (en) 2014-05-01 2019-03-20 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドEiger Biopharmaceuticals, Inc. デルタ肝炎ウイルス感染の治療
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
EP3370723B1 (en) 2015-11-04 2020-12-16 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR20180110127A (ko) 2016-02-19 2018-10-08 아이거 바이오파마슈티컬스 인코포레이티드 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료
CN113286605A (zh) 2018-08-23 2021-08-20 艾格尔峰生物制药有限公司 用干扰素λ治疗丁型肝炎病毒感染

Also Published As

Publication number Publication date
JP2018517673A (ja) 2018-07-05
DK3285768T3 (da) 2021-01-25
US10835496B2 (en) 2020-11-17
US11517532B2 (en) 2022-12-06
ES2844848T3 (es) 2021-07-22
KR20220147695A (ko) 2022-11-03
EP3285768A4 (en) 2019-01-09
US20210093571A1 (en) 2021-04-01
KR102514971B1 (ko) 2023-03-27
KR20170138540A (ko) 2017-12-15
EP3285768B1 (en) 2020-12-30
WO2016172342A1 (en) 2016-10-27
US20180110734A1 (en) 2018-04-26
EP3285768A1 (en) 2018-02-28
US12029819B2 (en) 2024-07-09
CN107530338A (zh) 2018-01-02
US20230218530A1 (en) 2023-07-13
CN107530338B (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
IL258082B (en) History of benzaimidazole and pharmaceutical preparations containing them
ZA201802003B (en) Dual function proteins and pharmaceutical composition comprising same
ZA201802125B (en) Pharmaceutical composition and application thereof
PT3426348T (pt) Derivado de 3-desoxi e composições farmacêuticas do mesmo
GB201608323D0 (en) Pharmaceutical compositions
IL252967B (en) Pharmaceutical preparations containing plasminogen and their uses
ZA201800487B (en) Lyophilized pharmaceutical compositions
HUE054068T2 (hu) Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
IL263040A (en) Pharmaceutical composition comprising eteplirsen
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
SG10202106375UA (en) Pharmaceutical compositions and use thereof
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
IL263999A (en) Pharmaceutical compositions
ZA201705782B (en) Pharmaceutical compositions
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201604810D0 (en) Pharmaceutical compositions and uses
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
ZA201705783B (en) Pharmaceutical compositions
GB201700831D0 (en) Pharmaceutical compositions